Cardiol Therapeutics Inc.

CRDL Nasdaq SEC CIK 1702123
Follow Cardiol Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 CAD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income7 fiscal years
−CAD 40M−CAD 30M−CAD 20M−CAD 10MCAD 0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−CAD 33.8M
FY24−CAD 36.7M
FY23−CAD 28.1M
FY22−CAD 30.9M
FY21−CAD 31.6M
FY20−CAD 20.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−CAD 30M−CAD 20M−CAD 10MCAD 0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−CAD 23.9M
FY24−CAD 25.1M
FY23−CAD 25.2M
FY22−CAD 27.3M
FY21−CAD 23.6M
FY20−CAD 9.2M
FY19-